Navigation Links
Blood Test To Predict Heart Failures

Researchers at Jefferson Medical College had discovered the existence of an enzyme in the blood that acts as a biomarker for conditions that lead to heart failures. Based on their findings they have now successfully developed // a blood test to predict the onset of heart failure in patients with cardiac disease.

Scientists had previously showed that an enzyme called GRK2 or beta-adrenergic kinase (?ARK1) is critically important in heart function. It is increased in failing human hearts and contributes to the loss of the heart’s contractile strength during the development of heart failure. Decreasing or inhibiting the enzyme reversed heart failure in laboratory tests.

In their latest findings, researchers have shown, using tissue samples from heart failure patients, that they could track heart levels of GRK2 in the blood.

The researchers reported their findings July 29 in an online article in advance of print in the European Heart Journal.

In the study, researchers had compared tissue samples from a group of 24 patients in heart failure who needed transplants to 58 patients who were not as sick, though had various stages of left ventricular malfunction. They found that the sicker patients had higher levels of GRK2 in the heart and in the blood.

Researchers feel that in future they would like to eventually perform large human trials to specifically look at levels of GRK2 to see if they can predict responses to drugs such as beta-blockers or other treatments for heart failure.

Researchers have known from animal studies that the expression of GRK2 appears to be regulated by hormones called catecholamines, which include norepinephrine and epinephrine, message-carrying neurotransmitters in the sympathetic nervous system.

In heart failure, the sympathetic nervous system is in overdrive, and levels of these hormones are high. In congestive heart failure, the beta-adrenergic receptor system fai ls to work properly. One of the functions of GRK2 or beta-adrenergic kinase (?ARK1) is to turn off beta-adrenergic receptors.

Source: Newswise
'"/>




Related medicine news :

1. Recommendations for Treatment of Blood Pressue
2. Blood Cells Capable of Regenerating Liver
3. Blood clots likely in long travel
4. Hemochromatosis Patients Blood is Safe
5. Blood transfusions beneficial after heart attacks
6. Blood Pressure Drug may slow wasting in burn victims
7. Levels Of Blood Proteins May Help Heart Disease Care
8. Blood test may identify ovarian cancer
9. A Blood test for suicide risk?
10. Blood Pressure Drugs maintain muscle strength
11. Blood test diagnoses heart failure in short time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... TX (PRWEB) , ... October 13, 2017 , ... ... planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, is ... boy fighting to overcome a rare and deadly chromosome abnormality. , After struggling ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of ... its next President and Chief Executive Officer, succeeding Dr. James C. Puffer upon his ... July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. Upon assuming ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... COPENHAGEN, Denmark , Oct. 2, 2017 The ... tool in the struggle to reverse the tide of prescription ... plan for regulating their medicine intake and stepping down their ... is set to launch in December 2017; the first 100,000 ... access. Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... 25, 2017   Montrium , an industry ... today—from the IQPC Trial Master Files & Inspection ... that EastHORN Clinical Services has selected eTMF ... TMF management. EastHORN, a leading European contract research ... increase transparency to enable greater collaboration with sponsors, ...
(Date:9/19/2017)... Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, ... tissues, announced three leadership team developments today:   ... ... ... Veteran medical device executive Josh Stopek , PhD, ...
Breaking Medicine Technology: